Clinical Trials Logo

Hypoglycemia clinical trials

View clinical trials related to Hypoglycemia.

Filter by:

NCT ID: NCT04971070 Completed - Hypoglycemia Clinical Trials

Analysis of Related Risk Factors of Hypoglycemia Consciousness Disorder

Start date: July 25, 2021
Phase:
Study type: Observational

Objective to explore the high risk factors and inducements of consciousness disorder in patients with hypoglycemia, and to conduct a retrospective study.

NCT ID: NCT04909333 Completed - Clinical trials for Endogenous Hyperinsulinism

Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

FAST
Start date: April 29, 2021
Phase: N/A
Study type: Interventional

This study is to evaluate the concept of the exenatide test for diagnosis of EHH (earlier induction of symptomatic hypoglycemia compared to placebo within 4 hours after injection).

NCT ID: NCT04876079 Completed - Type 1 Diabetes Clinical Trials

Prevention of Mild-to-moderate Hypoglycemia in Type 1 Diabetes

REVERSIBLE
Start date: June 1, 2021
Phase: N/A
Study type: Interventional

According to guidelines, when a mild-to-moderate hypoglycemia occurs (capillary blood glucose < 4.0 mmol/L), 15-20g of rapidly absorbed carbohydrates should be ingested. Patients should re-test and re-ingest 15-20g carbohydrates every 15 minutes until they recover from hypoglycemia. These recommendations were principally based on two studies conducted in the 80s before the introduction of intensive insulin therapy. In practice, only 32-50% of patients follow the current guidelines. In addition, recent studies suggest that under current intensive insulin therapies, an initial correction with 15g of oral glucose may be insufficient to rapidly correct mild-to-moderate hypoglycemia. With the development and increasing usage of newer glucose monitoring technologies, the community is witnessing a shift in hypoglycemia management, from a reactive to a proactive approach (e.g., prevent imminent episodes rather than treating established episodes).

NCT ID: NCT04864483 Completed - Type1diabetes Clinical Trials

Sahoor Meal Regimen for Patients With Type1 Diabetes

Start date: March 21, 2021
Phase: N/A
Study type: Interventional

To examine effects of two approaches to sahoor meal consumption during Ramadan on blood sugar control and incidence of early day hypoglycemic episodes requring the discontinuation of fasting.

NCT ID: NCT04862390 Completed - Clinical trials for Pregnancy in Diabetic

Incidence of Hypoglycemia in Pregnant Ladies With or Without Gestational Diabetes Fasting Ramadan

Start date: March 28, 2021
Phase:
Study type: Observational

The physiological change in food and sleep pattern during Ramadan impacted hypoglycemia risks among pregnant women. Few studies investigated the incidence of hypoglycemia pregnant women with or without diabetes during fasting in Ramadan in Saudi Arabia. This study aims to understand the glucose variability in pregnant women during fasting Ramadan in Saudi Arabia.

NCT ID: NCT04836273 Completed - Clinical trials for Postprandial Hypoglycemia

Treatment of Post-bariatric Hypoglycaemia

SHERRY
Start date: August 20, 2021
Phase: Phase 2
Study type: Interventional

This is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, single-centre phase II study aiming to evaluate the efficacy, safety and tolerability of self-administered subcutaneous 120 µg dasiglucagon with an investigational trial device (i.e. a multi-dose reusable pen) for the treatment of postprandial hypoglycaemia after Roux-en-Y gastric bypass (RYGB) surgery. The study is divided into an in-patient and out-patient part. The primary aim of the study is to compare the effects of self-administered 120 µg dasiglucagon versus placebo on continuous glucose monitoring (CGM)-assessed time spent in hypoglycaemia in RYGB-operated individuals in an out-patient setting.

NCT ID: NCT04764968 Completed - Type 1 Diabetes Clinical Trials

Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes

Start date: April 27, 2021
Phase: Phase 2
Study type: Interventional

The aim of the study is to evaluate the efficacy, safety and feasibility of outpatient-utilization of low-dose dasiglucagon administered via a multi-dose reusable pen injector in preventing and treating mild hypoglycemia in insulin pump-treated people with type 1 diabetes.

NCT ID: NCT04721145 Completed - Type 1 Diabetes Clinical Trials

CGM Use in Poorly Controlled Youth With Type 1 Diabetes

IMPaCT
Start date: January 25, 2021
Phase: N/A
Study type: Interventional

The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system for a 10 day wear period in high risk, poorly controlled pediatric Type 1 diabetes patients increases uptake of personal CGM use, and improves short-term time in range glucose control.

NCT ID: NCT04712266 Completed - Clinical trials for Type 1 Diabetes Mellitus With Hypoglycemia

A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes

Start date: September 15, 2020
Phase: Early Phase 1
Study type: Interventional

This is a single center, double-blind, randomized trial in subjects with type 1 diabetes mellitus applying an adaptive design approach.

NCT ID: NCT04692623 Completed - Hypoglycemia Clinical Trials

EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE AND ECG MORPHOLOGY OF EUGLYCEMICS:A CLINICAL STUDY

CT
Start date: March 1, 2021
Phase: Phase 1
Study type: Interventional

EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE LEVEL OF EUGLYCEMICS:A PRE-CLINICAL AND CLINICAL STUDY. Our aim and objectives are to: 1. To check the possible effects of Moxifloxacin and Gemifloxacin in healthy volunteers for possible effects on blood glucose levels with a subsequent shift in serum insulin level of healthy volunteer (target population). 2. ECG morphology effect. In the above entitled studies we are going to determine the effects of the above two 4th generation fluoroquinolones drugs on the blood glucose levels and ECG morphology effect.of euglycemics healthy volunteers.The drug will be gave as per approved standard adult dose.The drug is FDA approved and marketed drug.No risk is to the patient only 3-5 ml of the blood will be taken at baseline and after the drug completion at steady state concentration.